Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

But making AbbVie an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV ...

Shares of AbbVie Inc. oscillated between gains and losses Friday as the company’s latest acquisition drew mixed reactions ...

Shares of AbbVie Inc. ABBV inched 0.10% higher to $173.37 Friday, on what proved to be an all-around mixed trading session ...

We recently published a list of 10 Best Safe Stocks To Buy According to Analysts. In this article, we are going to take a ...

AbbVie Inc. is a strong investment opportunity with promising drugs, steady dividends, and attractive growth potential. Find ...

AbbVie has entered into a definitive agreement to acquire Nimble Therapeutics in a deal valued at $200m in cash.

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...

Friday announced an agreement to acquire Nimble Therapeutics for a cash payment of $200 million at closing, along ...

On Monday, AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.67 which represents a decrease of $-0.90 or -0.51% from the prior close of $176.57. The stock opened at $175.53 and touched a low of $173.

AbbVie Inc (ABBV) stock saw a modest uptick, ending the day at $176.19 which represents a slight increase of $0.02 or 0.01% from the prior close of $176.17. The stock opened at $176 and touched a low ...